

OPEN

# NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

Jose Manuel Sánchez-Maldonado<sup>1,2</sup>, Manuel Martínez-Bueno<sup>3</sup>, Helena Canhão<sup>4</sup>, Rob ter Horst<sup>5</sup>, Sonia Muñoz-Peña<sup>1</sup>, Ana Moñiz-Díez<sup>1</sup>, Ana Rodríguez-Ramos<sup>6</sup>, Alejandro Escudero<sup>8</sup>, Signe B. Sorensen<sup>9,10</sup>, Merete L. Hetland<sup>11,12</sup>, Miguel A. Ferrer<sup>13</sup>, Bente Glintborg<sup>11,12</sup>, Ileana Filipescu<sup>14</sup>, Eva Pérez-Pampin<sup>15</sup>, Pablo Conesa-Zamora<sup>16</sup>, Antonio García<sup>13</sup>, Alfons den Broeder<sup>17</sup>, Salvatore De Vita<sup>18</sup>, Svend Erik Hove Jacobsen<sup>19</sup>, Eduardo Collantes<sup>8</sup>, Luca Quartuccio<sup>18</sup>, Mihai G. Netea<sup>5,6</sup>, Yang Li<sup>5,7</sup>, João E. Fonseca<sup>20,21</sup>, Manuel Jurado<sup>1,2</sup>, Miguel Ángel López-Nevo<sup>2,22</sup>, Marieke J. H. Coenen<sup>17</sup>, Vibeke Andersen<sup>9,10</sup>, Rafael Cáliz<sup>1,2,13</sup> & Juan Sainz<sup>1,2\*</sup>

This study sought to evaluate the association of 28 single nucleotide polymorphisms (SNPs) within NFKB and inflammasome pathway genes with the risk of rheumatoid arthritis (RA) and response to TNF inhibitors (TNFi). We conducted a case-control study in a European population of 1194 RA patients and 1328 healthy controls. The association of potentially interesting markers was validated with data from the DANBIO (695 RA patients and 978 healthy controls) and DREAM (882 RA patients) registries. The meta-analysis of our data with those from the DANBIO registry confirmed that anti-citrullinated protein

<sup>1</sup>Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain. <sup>2</sup>Instituto de Investigación Biosanitaria IBs. Granada, Granada, Spain. <sup>3</sup>Area of Genomic Medicine, GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain. <sup>4</sup>CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa, Lisbon, Portugal. <sup>5</sup>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. <sup>6</sup>Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, 53115, Bonn, Germany. <sup>7</sup>Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. <sup>8</sup>Rheumatology department, Reina Sofía Hospital/IMIBIC/University of Córdoba, Córdoba, Spain. <sup>9</sup>Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Hospital of Southern Jutland, DK-6200, Aabenraa, Denmark. <sup>10</sup>Institute of Molecular Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. <sup>11</sup>The DANBIO registry, The Danish Rheumatologic Biobank and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. <sup>12</sup>Department of Clinical, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>13</sup>Rheumatology department, Virgen de las Nieves University Hospital, Granada, Spain. <sup>14</sup>Rheumatology department, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. <sup>15</sup>Rheumatology Unit, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. <sup>16</sup>Clinical Analysis department, Santa Lucía University Hospital, Cartagena, Spain. <sup>17</sup>Radboud university medical center, Radboud Institute for Health Sciences, Department of Human Genetics, Nijmegen, The Netherlands. <sup>18</sup>Department of Medical Area, Clinic of Rheumatology, University of Udine, Udine, Italy. <sup>19</sup>Department of Biochemistry and Immunology. University Hospital of Southern Jutland, Jutland, Denmark. <sup>20</sup>Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHLN, Lisbon, Portugal. <sup>21</sup>Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Center, Lisbon, Portugal. <sup>22</sup>Immunology department. Virgen de las Nieves University Hospital, Granada, Spain. \*email: [juan.sainz@genyo.es](mailto:juan.sainz@genyo.es)

antibodies (ACPA)-positive subjects carrying the *NFKB2*<sub>rs11574851T</sub> allele had a significantly increased risk of developing RA (PMeta\_ACPA+ = 0.0006) whereas no significant effect was found in ACPA-negative individuals (PMeta\_ACPA- = 0.35). An ACPA-stratified haplotype analysis including both cohorts (n = 4210) confirmed that ACPA-positive subjects carrying the *NFKB2*<sub>TT</sub> haplotype had an increased risk of RA (OR = 1.39, P = 0.0042) whereas no effect was found in ACPA-negative subjects (OR = 1.04, P = 0.82). The meta-analysis of our data with those from the DANBIO and DREAM registries also revealed a suggestive association of the *NFKB2*<sub>rs1056890</sub> SNP with larger changes in DAS28 (OR = 1.18, P = 0.007). Functional experiments showed that peripheral blood mononuclear cells from carriers of the *NFKB2*<sub>rs1005044C</sub> allele (in LD with the rs1056890, r<sup>2</sup> = 1.00) showed increased production of IL10 after stimulation with LPS (P = 0.0026). These results provide first evidence of a role of the *NFKB2* locus in modulating the risk of RA in an ACPA-dependent manner and suggest its implication in determining the response to TNFi. Additional studies are now warranted to further validate these findings.

Rheumatoid arthritis (RA) is a chronic inflammatory disease more frequently diagnosed in females than males, that has a prevalence of about 0.5–1%. RA perpetuates and amplifies itself through a wide number of molecular mechanisms involving several immune cell types and multiple inflammatory mediators that are released from the damaged tissue<sup>2</sup>. Although the complexity of inflammatory pathways implicated in RA development and progression remains in part unknown, there are convincing evidences supporting the view that *NFKB* pathway and its connection with the NLRP3-inflammasome plays a pivotal role in the modulation of the expression of multiple inflammatory genes implicated in RA development<sup>3</sup> and drug response or disease progression<sup>4</sup>.

Activated *NFKB* has been detected in the synovium of RA patients at both early and late stages of joint inflammation<sup>5–8</sup> and once *NFKB* is activated (for instance, through the interaction of antigen presenting cells and T cells), it triggers two major signaling pathways in the implicated cells: the canonical and the non-canonical *NFKB* pathway. Whereas the canonical pathway regulates the activation of *NFKB1 p50*, *RELA* and *c-REL* and leads to rapid but transient *NFKB* activation, the non-canonical *NFKB* pathway selectively activates p100-sequestered *NFKB* members (predominantly *NFKB2 p52* and *RELB*) and produces a long-lasting signaling. Even though a cross-talk between the canonical and non-canonical *NFKB* pathways has been previously reported, the activation of the canonical *NFKB* pathway is generally associated with inflammation whereas the induction of the non-canonical *NFKB* pathway was linked to development processes<sup>9</sup>. In RA, it is well known that the acute activation of the canonical pathway on antigen presenting cells and T cells quickly leads to the production of a wide range of essential proinflammatory mediators including cytokines (TNF $\alpha$ , IL1 $\alpha$ , IL1 $\beta$ , IL1RA, IL2, IL12p40 and IFN $\gamma$ ), chemokines (IL8, CXCL11), immunoreceptors (CD80, CD23, CD48, CD69, IL2R, TNFRs, and CCR5), cell adhesion molecules (ELAM-1, ICAM-1, VCAM-1 and P-selectin) and growth factors (GM-CSF, IGFBP2, and PDGFB) that often facilitate synovial hyperplasia by promoting cell proliferation and apoptosis inhibition of RA fibroblast-like synovial cells<sup>10</sup>. On the contrary, the activation of the non-canonical pathway involves a slow build-up of long-lasting signals that have been implicated in developmental processes including B-cell development<sup>11</sup>, secondary lymphoid organ development<sup>12,13</sup> and osteoclast differentiation<sup>14</sup> but also development of myeloid-related CD4<sup>+</sup>CD8 $\alpha$ <sup>-</sup> dendritic cells and macrophages<sup>15</sup>, key players in modulating immune responses in RA.

Besides the role of *NFKB* in the inflammatory process, recent evidences have shown that the NLRP3-inflammasome is a cytosolic multiprotein complex highly expressed in peripheral blood mononuclear cells of RA patients and in the synovial tissues of osteoarthritis patients. The NLRP3 inflammasome is capable of alerting immune system to the presence of tissue damage and to induce the processing of the IL1 $\beta$ , IL18 and IL33 pro-cytokines into biologically active proinflammatory mediators that drive cartilage destruction<sup>16</sup>. In addition, it has been reported that the presence of mutations in NLRP3-inflammasome-related proteins (*CARD8* and *NLRP3*) predispose to RA<sup>17,18</sup> and that genetic variation in this pathway might also modulate inflammatory activity in early stages of the disease and thereby affect disease progression<sup>17,18</sup>.

Considering the aspects detailed above, but also previous studies suggesting that the *NFKB*- and NLRP3-inflammasome pathways are genetically determined<sup>19</sup>, we decided to conduct a case-control study to investigate whether 28 single nucleotide polymorphisms (SNPs) within the *NFKB1*, *NFKB2*, *NFKBIB*, *IKKBK*, *GBP6*, *IRF4*, *NLRP3*, *REL*, *RELA*, *KLRC1*, *KLRK1* | *KLRC4*, *LOC105376246* (ncRNA), *TLR4*, *TLR5*, *TLR9*, *TLR10* and *TRAF1* | *C5* genes influence the risk of developing RA and the response to TNF inhibitors (TNFi). In addition, we investigated the correlation of selected SNPs with steroid hormone levels and their role in modulating immune responses after stimulation of whole blood, peripheral mononuclear cells (PBMCs) and macrophages with lipopolysaccharide (LPS), phytohemagglutinin (PHA) and Pam3Cys.

## Material and Methods

**Discovery population.** The discovery population consisted of 1194 RA patients and 1328 healthy controls ascertained through the REPAIR consortium (Table 1). RA patients fulfilled the 1987 revised American College of Rheumatology (ACR)<sup>20</sup> and the ACR/EULAR 2010 classification criteria<sup>21</sup>. The study followed the Declaration of Helsinki. Study participants were of European origin and gave their written informed consent to participate in the study, which was approved by the ethical review committee of participant institutions. The Ethics committee of each participant institution approved the study protocol: Virgen de las Nieves University Hospital (2012/89); Santa Maria Hospital-CHLN (CE 877/121.2012); University Clinical Hospital of Santiago de Compostela (2013/156). A detailed description of the discovery population has been reported elsewhere<sup>22–24</sup>.

RA patient populations			
Demographic characteristics	Discovery Population (n = 1194)	DREAM <sup>†</sup> Registry (n = 882)	DANBIO Registry (n = 695)
Age (years)	59.22 ± 12.97	54.63 ± 12.80	54.27 ± 13.30
Gender ratio (female/male)	4.01 (959/234)	2.07 (477/230)	2.80 (512/183)
Clinical assessment			
RF positive patients*	764 (68.64)	534 (77.62)	221 (64.06)
ACPA positive patients*	643 (70.74)	151 (62.14)	390 (72.90)
DAS28 at baseline	5.74 ± 2.15	5.33 ± 1.26	4.77 ± 1.23
Disease duration (years)	17.60 ± 9.99	9.70 ± 9.57	7.89 ± 8.86
Treatments			
csDMARDs at baseline			
Methotrexate (%)	798 (66.83)	463 (65.40)	514 (73.95)
Leflunomide (%)	324 (27.14)	ND	ND
Sulphasalazine (%)	149 (12.48)	ND	ND
First biologic agent			
Infliximab (%)	386 (32.33)	244 (34.46)	159 (22.88)
Etanercept (%)	227 (19.01)	130 (18.36)	200 (28.78)
Adalimumab (%)	191 (16.00)	334 (47.18)	173 (24.89)
Golimumab (%)	17 (01.42)	—	47 (06.76)
Certolizumab (%)	—	—	72 (10.36)
Rituximab (%)	13 (01.09)	—	16 (02.30)
Tocilizumab (%)	6 (00.50)	—	19 (02.73)
Anakinra (%)	—	—	2 (00.29)
Others (%)	14 (01.17)	—	7 (01.01)

**Table 1.** Demographic and clinical characteristics of RA patients. Data are means ± standard deviation or n (%). Abbreviations: RF, rheumatoid factor; ACPA: anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs. ND, not determined (unknown). <sup>†</sup>Clinical data for 708 RA patients that were available for genotyping. \*RF was available for 1113, 688 and 345 patients in the discovery, DREAM and DANBIO populations, respectively. \*ACPA was available for 908, 127 and 535 patients in the discovery, DREAM and DANBIO populations, respectively.

**Response to anti-TNF medications.** Six hundred and four RA patients treated with TNFi (adalimumab, etanercept, infliximab, golimumab or certolizumab) were included in the drug response analysis of the discovery population. The change in disease activity score (DAS28) at baseline and at 6 months of treatment with TNFi was calculated for each patient. Linear regression analysis adjusted for age and sex was used to determine the association between selected SNPs and changes in DAS28. Subjects with missing values for DAS28 in any of these time points were not included in the analysis.

**SNP selection and genotyping.** NFKB- and inflammasome-related polymorphisms were selected on the basis of their potential functionality and linkage disequilibrium (LD) but also because of existing studies reporting their significant association with the risk of developing autoimmune and immune-related diseases or response to TNFi<sup>25–29</sup>. This strategy resulted in the selection of 28 genetic variants within the *GBP6*, *IKBKB*, *IRF4*, *KLRC1*, *KLRK1*, *NFKB1*, *NFKB2*, *NFKBIB*, *NLRP3*, *REL*, *RELA*, *RELB*, *TLR4*, *TLR5*, *TLR9*, *TLR10* and *TRAF1/C5* loci that were genotyped in the discovery population (Table 2). Genomic DNA was extracted from peripheral blood using the Qiagen Mini Kit (Qiagen, CA, USA) or from saliva using standard procedures. Genotyping was carried out using KASPar<sup>®</sup> assays (LGC Genomics, London, UK) in a 384-well plate format (Applied Biosystems, CA, USA) according to manufacturer's instructions. Five percent of samples were included as duplicates to ensure high-quality genotyping.

**Statistical analysis.** The Hardy-Weinberg Equilibrium (HWE) test was performed in the control group by a standard observed-expected chi-square ( $\chi^2$ ). Logistic and linear regression analyses adjusted for age, sex and country of origin were used to assess the main effects of the selected SNPs on RA risk and the response to TNFi respectively. Statistical power was estimated using Quanto software (<http://hydra.usc.edu/gxe/>). Correction for multiple testing was performed using the Meff method for SNPs genotyped across all populations<sup>30</sup>. The threshold used for the risk and drug response analyses was 0.0008 ([0.05/22 independent markersx3 inheritance models]).

**Linkage disequilibrium (LD) and haplotype analysis.** We performed haplotype frequency estimation and haplotype association analysis adjusted for age, sex and country of origin using SNPstats<sup>31</sup> and haplo.stats package in STATA. Haplotype frequencies were determined using the Expectation-maximization (EM) algorithm. Haplotypes were reconstructed using SNPtool and Haploview and block structures were determined according to the method of Gabriel *et al.*<sup>32</sup>.

Gene	Chr.	dbSNP rs#	Nucleotide substitution	Effect-allele	Location	Reported associations with autoimmune diseases, drug response and/or potential functional role
<i>GBP6</i>	1	rs928655	A/G	A	Intronic	Associated with etanercept response in moderate-to-severe plaque psoriasis <sup>47</sup>
<i>IKBKB</i>	8	rs11986055	A/C	A	Intronic	
<i>IRF4</i>	6	rs1050975	A/G	A	3'-UTR/ncRNA	
<i>IRF4</i>	6	rs12203592	C/T	T	Intronic	Correlated with white blood cell count <sup>48</sup>
<i>IRF4</i>	6	rs1877175	C/T	T	3'-UTR/ncRNA	
<i>IRF4</i>	6	rs7768807	T/C	T	3'-UTR/ncRNA	
<i>KLRC1</i>	12	rs7301582	C/T	T	Intronic	Associated with response to anti-TNF therapy in RA patients <sup>49</sup>
<i>KLRK1 KLRC4</i>	12	rs1049174	C/G	C	3'UTR/Intronic	Associated with response to anti-TNF therapy in RA patients <sup>50</sup>
<i>KLRK1 KLRC4</i>	12	rs1154831	A/C	A	Intronic/Near gene	Lack of association with response to anti-TNF therapy <sup>50</sup>
<i>KLRK1 KLRC4</i>	12	rs2255336	A/G	A	Thre72Ala	Correlation with blood NKG2D type II integral membrane protein levels <sup>51</sup> and associated with response to anti-TNF therapy in RA patients <sup>50</sup> ; Associated with a decreased risk of Lupus erythematosus <sup>52,53</sup>
<i>LOC105376246</i>	9	rs2722824	A/C	A	Near gene	
<i>NFKB1</i>	4	rs4648110	A/T	A	Intronic	
<i>NFKB2</i>	10	rs11574851	C/T	T	Asn698Asn	
<i>NFKB2</i>	10	rs12769316	C/T	T	Near gene	
<i>NFKB2 PSD</i>	10	rs1056890	C/T	T	Near gene/3'-UTR	
<i>NFKBIB</i>	19	rs3136645	C/T	C	ncRNA	Associated with response to anti-TNF drugs in RA patients <sup>25</sup>
<i>NLRP3</i>	1	rs4612666	C/T	T	Intronic	Associated with response to anti-TNF drugs in RA patients <sup>42</sup>
<i>REL</i>	2	rs13031237	G/T	T	Intronic	Overall association with the risk of RA at GWAS level <sup>29,54,55</sup> . Association with RA in ACPA-positive individuals at GWAS level <sup>55</sup> ; Association with early-onset psoriasis <sup>56</sup> and autoimmune diseases <sup>37</sup> in large candidate gene association studies
<i>REL</i>	2	rs842647	A/G	A	Intronic	Associated with susceptibility to Behcet's disease <sup>58</sup>
<i>REL</i>	2	rs13017599	A/G	A	Near gene	Associated with RA and psoriatic arthritis at GWAS level <sup>29,59</sup> and in a candidate gene association study <sup>60</sup>
<i>RELA</i>	11	rs11820062	C/T	T	Intronic	Eosinophil counts <sup>48</sup>
<i>RELA</i>	11	rs2306365	A/G	A	Intronic	
<i>RELA</i>	11	rs7119750	C/T	T	Intronic	
<i>TLR10</i>	4	rs11096957	A/C	A	Asn241His	Associated with hip osteoarthritis <sup>61,62</sup> and effectiveness of biologics for psoriasis treatment at GWAS level <sup>63</sup>
<i>TLR4</i>	9	rs4986791	C/T	T	Thr399Ile	TLR4: lymphocyte 96 antigen complex level <sup>51</sup> ; Associated with RA risk and response to anti-TNF drugs <sup>64</sup> ; Associated with risk of developing inflammatory bowel disease <sup>65</sup>
<i>TLR5</i>	1	rs5744174	C/T	C	Phe616Leu	Associated with response to anti-TNF drugs in RA patients <sup>27</sup> ; Associated with the risk of Crohns disease <sup>66</sup> and response to anti-TNF treatment <sup>67</sup> ; Associated with response to ustekinumab treatment in psoriasis patients <sup>68</sup>
<i>TLR9  TWF2</i>	3	rs187084	G/A	T	Near gene	Associated with psoriatic arthritis risk <sup>69</sup> , hip and knee osteoarthritis <sup>70,71</sup> , SLE <sup>72</sup> and IBD <sup>73</sup> ; associated with the risk of autoimmune thyroid disease <sup>74</sup> ; response to anti-TNF therapy in patients with RA <sup>64</sup> and IBD <sup>75</sup>
<i>TRAF1  C5</i>	9	rs3761847	A/G	A	Near gene	Associated with RA at GWAS level <sup>54,76</sup>

**Table 2.** Selected SNPs within NFKB-related genes. Abbreviations: SNP, single nucleotide polymorphism; UTR, untranslated region; ncRNA, non-coding Ribonucleic acid. Risk alleles were select according to available GWAS data in order to make possible a meta-analysis of the discovery and replication cohorts.

**Replication populations and meta-analyses for RA risk and drug response.** For replication purposes, we genotyped the most promising SNPs associated with RA risk in a cohort of 695 Danish RA patients and 978 healthy controls<sup>33</sup>. Clinical data from RA patients were collected through the DANBIO registry (The National

Danish Registry for Biological Treatment of Rheumatic Diseases)<sup>34</sup> and DNA samples were obtained from peripheral blood collected at the Statens Serum Institut (Copenhagen, Denmark), which routinely perform screening for tuberculosis before treatment with biological treatments. Healthy blood donors were recruited in Viborg and Sønderborg (Denmark). In order to replicate the most interesting associations with response to TNFi, we also used genetic data from a genome-wide association study (GWAS) on drug response conducted in 882 Dutch RA patients from the DREAM (Dutch Rheumatoid Arthritis Monitoring) registry. Imputed SNPs reporting potentially interesting overall or ACPA-specific associations with RA risk or drug response were genotyped in a subset of 708 patients. To further validate our results, we also genotyped the most interesting markers associated with drug response in 555 RA patients from the DANBIO registry that were treated with TNFi. A total of 2107 patients were treated with anti-TNF. Demographic and clinical details of the 3 cohorts are included in Supplementary Table 1. The study was approved by the Institutional review board of the Radboud university medical centre and by the Regional Ethics Committee of Central Denmark Region (M-20100153 and S-20120113). All patients provided written informed consent and clinical information was prospectively gathered from the medical records.

To test for genetic association, we conducted a meta-analysis of the discovery data with those from the 2 European registries and the  $I^2$  statistic was used to assess statistical heterogeneity between studies. The pooled OR was computed using the random-effect model.

**Functional analysis of the NFKB and inflammasome-related variants.** Cytokine stimulation experiments were conducted in the 500 Functional Genomics (500FG) cohort from the Human Functional Genomics Project (HFGP; <http://www.humanfunctionalgenomics.org/>), which was designed to determine the influence of genomic variation on the variability of immune responses. The HFGP study was approved by the Arnhem-Nijmegen Ethical Committee (no. 42561.091.12) and biological specimens (venous blood) were collected after informed consent was obtained. We assessed whether any of the 28 NFKB and inflammasome-related SNPs correlated with cytokine levels (TNF $\alpha$ , IFN $\gamma$ , IL1 $\beta$ , IL1RA, IL6, IL8, IL10, IL17, and IL22) after the stimulation of whole blood, peripheral blood mononuclear cells (PBMCs) or monocyte-derived macrophages from 408 healthy subjects with LPS (1 or 100 ng/ml), PHA (10  $\mu$ g/ml), and Pam3Cys (10  $\mu$ g/ml). After log transformation, linear regression analyses adjusted for age and sex were used to determine the correlation of selected SNPs with cytokine expression quantitative trait loci (cQTLs). All analyses were performed using R software (<http://www.r-project.org/>). In order to account for multiple comparisons, we used a significant threshold of 0.00025, i.e. 0.05/(22 independent SNPs  $\times$  9 cytokines).

Details on PBMCs isolation, macrophage differentiation and stimulation assays have been reported elsewhere<sup>35–37</sup>. Briefly, PBMCs were washed twice in saline and suspended in medium (RPMI 1640) supplemented with gentamicin (10 mg/mL), L-glutamine (10 mM) and pyruvate (10 mM). PBMC stimulations were performed with  $5 \times 10^5$  cells/well in round-bottom 96-wells plates (Greiner) for 24 hours in the presence of 10% human pool serum at 37 °C and 5% CO<sub>2</sub>. Supernatants were collected and stored in –20 °C until used for ELISA. LPS (100 ng/ml), PHA (10  $\mu$ g/ml) and Pam3Cys (10  $\mu$ g/ml) were used as stimulators for 24 or 48 hours. Whole blood stimulation experiments were conducted using 100  $\mu$ l of heparin blood that was added to a 48 well plate and subsequently stimulated with 400  $\mu$ l of LPS and PHA (final volume 500  $\mu$ l) for 48 hours at 37 °C and 5% CO<sub>2</sub>. Supernatants were collected and stored in –20 °C until used for ELISA. Concentrations of human TNF $\alpha$ , IFN $\gamma$ , IL1 $\beta$ , IL1RA, IL6, IL8, IL10, IL17, and IL22 were determined using specific commercial ELISA kits (PeliKine Compact, Amsterdam, or R&D Systems), in accordance with the manufacturer's instructions.

Once we examined the correlation of NFKB and inflammasome-related polymorphisms with cytokine levels in our functional experiments, we also used the HaploReg SNP annotation tool (<http://www.broadinstitute.org/mammals/haploreg/haploreg.php>) to further investigate the functional consequences of each specific variant. We also assessed whether any of the potentially interesting markers correlated with mRNA expression levels of their respective genes using data from GTeX portal ([www.gtexportal.org/home/](http://www.gtexportal.org/home/)).

**Correlation between steroid hormone levels and NFKB- and inflammasome-related SNPs.** We also measured serum levels of seven steroid hormones (androstenedione, cortisol, 11-deoxy-cortisol, 17-hydroxy progesterone, progesterone, testosterone and 25 hydroxy vitamin D3) in the 500FG cohort, which includes 531 healthy subjects. Steroid hormones were analyzed by Liquid Chromatography Tandem-Mass Spectrometry (LCMSMS) after protein precipitation and solid-phase extraction as described in Ter Horst *et al.*<sup>37</sup> (see also Supplementary Material). Hormone levels and genotyping data were available for a total of 406 subjects.

After log-transform, correlation between steroid hormone levels and NFKB- and inflammasome-related SNPs was evaluated by linear regression analysis adjusted for age and sex. In order to avoid a possible bias, we excluded those subjects that were using oral contraceptives or those subjects in which this information was not known from the analysis. A total of 379 healthy subjects (107 women and 272 men) were finally available for analysis. A Bonferroni significance threshold was set to 0.00033 considering the number of independent SNPs tested ( $n = 22$ ) and the number of hormones determined ( $n = 7$ ).

## Results

This study was conducted in a discovery population comprised of 1194 RA patients and 1328 healthy controls. RA patients were slightly older than controls ( $59.22 \pm 12.97$  vs.  $52.67 \pm 8.99$ ) and showed an increased female/male ratio compared to healthy controls (4.10 [959/234] vs. 1.39 [773/555]). Sixty percent of the RA patients presented positive values of anti-citrullinated protein antibodies (ACPA) and the median disease duration was of 17.60 years and the disease activity score 28 (DAS28) calculated at patient recruitment was of 5.74 (Table 1).

**Association of selected SNPs with RA risk.** All SNPs were in Hardy-Weinberg equilibrium in the control group ( $P > 0.001$ ). Logistic regression analysis adjusted for age, sex and country of origin showed that carriers

Gene	SNP ID	Chr.	Effect allele	Overall RA (n = 2521) 1193 RA/1328 Controls		ACPA <sup>+</sup> RA patients (n = 1971) 643 RA/1328 Controls		ACPA <sup>-</sup> RA patients (n = 1593) 265 RA/1328 Controls	
				OR (95% CI) <sup>o</sup>	P	OR (95% CI) <sup>o</sup>	P	OR (95% CI) <sup>o</sup>	P
<i>GBP6</i>	rs928655	1	A	0.94 (0.81–1.08)	0.37	0.88 (0.74–1.04)	0.14	1.08 (0.84–1.38)	0.54
<i>IKBKB</i>	rs11986055	8	A	0.93 (0.71–1.21)	0.59	1.15 (0.83–1.62)	0.40	0.99 (0.65–1.53)	0.98
<i>IRF4</i>	rs1050975	6	A	<b>1.30 (1.04–1.62)<sup>s</sup></b>	<b>0.019</b>	<b>1.51 (1.14–1.99)<sup>s</sup></b>	<b>0.003</b>	1.30 (0.91–1.86) <sup>s</sup>	0.15
<i>IRF4</i>	rs12203592	6	T	0.97 (0.81–1.18)	0.79	0.99 (0.78–1.24)	0.92	0.83 (0.60–1.17)	0.29
<i>IRF4</i>	rs1877175	6	T	1.00 (0.86–1.16)	0.98	0.97 (0.80–1.16)	0.70	1.04 (0.82–1.32)	0.74
<i>IRF4</i>	rs7768807	6	T	0.95 (0.83–1.10)	0.51	0.93 (0.78–1.09)	0.36	1.03 (0.82–1.30)	0.78
<i>KLRC1</i>	rs7301582	12	T	<b>1.15 (1.00–1.34)<sup>t</sup></b>	<b>0.050</b>	1.05 (0.84–1.30) <sup>t</sup>	0.67	<b>1.56 (1.18–2.09)<sup>t</sup></b>	<b>0.002</b>
<i>KLRK1 KLRC4</i>	rs1049174	12	C	1.18 (0.99–1.41) <sup>t</sup>	0.068	1.09 (0.88–1.35) <sup>t</sup>	0.42	<b>1.38 (1.03–1.84)<sup>t</sup></b>	<b>0.031</b>
<i>KLRK1 KLRC4</i>	rs1154831	12	A	1.00 (0.86–1.16)	0.99	1.05 (0.88–1.26)	0.59	0.92 (0.71–1.17)	0.48
<i>KLRK1 KLRC4</i>	rs2255336	12	A	1.10 (0.94–1.27)	0.22	1.04 (0.87–1.25)	0.68	1.33 (0.99–1.77) <sup>t</sup>	0.055
<b>LOC105376246</b>	<b>rs2722824</b>	<b>9</b>	<b>A</b>	<b>0.96 (0.83–1.10)</b>	<b>0.53</b>	<b>0.93 (0.79–1.10)</b>	<b>0.41</b>	<b>1.08 (0.86–1.36)</b>	<b>0.50</b>
<i>NFKB1</i>	rs4648110	4	A	1.28 (0.85–1.93) <sup>s</sup>	0.23	<b>1.65 (1.04–2.63)<sup>s</sup></b>	<b>0.031</b>	0.86 (0.39–1.90) <sup>s</sup>	0.90
<i>NFKB2</i>	rs11574851	10	T	1.17 (0.93–1.48)	0.19	<b>1.39 (1.06–1.83)</b>	<b>0.017</b>	1.02 (0.68–1.52)	0.93
<i>NFKB2</i>	rs12769316	10	T	<b>1.70 (1.04–2.78)<sup>s</sup></b>	<b>0.034</b>	1.70 (0.95–3.06) <sup>s</sup>	0.077	<b>2.53 (1.24–5.14)<sup>s</sup></b>	<b>0.011</b>
<i>NFKB2 PSD</i>	rs1056890	10	T	0.96 (0.84–1.09)	0.54	0.95 (0.81–1.12)	0.56	1.01 (0.82–1.25)	0.90
<i>NFKBIB</i>	rs3136645	19	C	1.07 (0.91–1.24)	0.42	1.15 (0.95–1.38)	0.14	0.81 (0.62–1.04)	0.10
<i>NLRP3</i>	rs4612666	1	T	<b>1.25 (1.05–1.49)<sup>t</sup></b>	<b>0.013</b>	<b>1.29 (1.04–1.60)<sup>t</sup></b>	<b>0.020</b>	1.18 (0.89–1.56) <sup>t</sup>	0.26
<i>REL</i>	rs13031237	2	T	1.16 (0.91–1.48) <sup>t</sup>	0.24	1.15 (0.85–1.53) <sup>s</sup>	0.36	<b>1.48 (1.02–2.15)<sup>s</sup></b>	<b>0.040</b>
<i>REL</i>	rs842647	2	A	1.08 (0.94–1.24)	0.30	1.10 (0.93–1.31)	0.27	1.05 (0.83–1.33)	0.68
<i>REL</i>	rs13017599	2	A	1.06 (0.93–1.20)	0.40	1.04 (0.89–1.21)	0.64	1.17 (0.95–1.43)	0.13
<i>RELA</i>	rs11820062	11	T	0.93 (0.82–1.06)	0.29	0.91 (0.78–1.05)	0.20	1.07 (0.88–1.31)	0.49
<i>RELA</i>	rs2306365	11	A	1.07 (0.89–1.29)	0.48	1.02 (0.81–1.28)	0.86	1.16 (0.86–1.57)	0.32
<i>RELA</i>	rs7119750	11	T	1.09 (0.91–1.32)	0.34	1.04 (0.82–1.30)	0.76	1.24 (0.93–1.65)	0.15
<i>TLR10</i>	rs11096957	4	A	1.12 (0.99–1.27)	0.066	1.13 (0.98–1.32)	0.10	1.08 (0.89–1.33)	0.43
<i>TLR4</i>	rs4986791	9	T	1.17 (0.89–1.54)	0.25	1.15 (0.83–1.60)	0.40	1.00 (0.63–1.58)	0.99
<i>TLR5</i>	rs5744174	1	C	0.99 (0.87–1.13)	0.86	1.03 (0.88–1.20)	0.75	0.89 (0.72–1.10)	0.27
<i>TLR9  TWF2</i>	rs187084	3	T	0.97 (0.85–1.10)	0.61	0.93 (0.80–1.09)	0.39	1.02 (0.83–1.25)	0.88
<i>TRAF1  C5</i>	rs3761847	9	A	0.97 (0.85–1.10)	0.61	1.00 (0.86–1.17)	0.99	0.91 (0.74–1.13)	0.39

**Table 3.** Overall and ACPA-specific associations of NFKB-related polymorphisms and risk of developing RA (discovery population). Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. <sup>o</sup>Estimates calculated according to an additive model of inheritance and adjusted for age, sex and country of origin. <sup>t</sup>Estimates calculated according to a dominant model of inheritance and adjusted for age, sex and country of origin. <sup>s</sup>Estimates calculated according to a recessive model of inheritance and adjusted for age, sex and country of origin.  $P \leq 0.05$  in bold. Data on anti-ccp was missing in 285 patients.

of the *NLRP3*<sub>rs4612666T</sub> allele or the *IRF4*<sub>rs1050975A/A</sub> and *NFKB2*<sub>rs12769316T/T</sub> genotypes had an increased risk of developing RA at nominal level of  $P \leq 0.05$  (OR<sub>Dom</sub> = 1.25, 95%CI 1.05–1.49,  $P = 0.013$ ; OR<sub>Rec</sub> = 1.30, 95%CI 1.04–1.62,  $P = 0.019$ ; and OR<sub>Rec</sub> = 1.70, 95%CI 1.04–2.78,  $P = 0.034$ ; Table 3). Interestingly, an ACPA-stratified analysis revealed that ACPA-positive subjects carrying the *NFKB1*<sub>rs4648110A/A</sub> genotype or the *NFKB2*<sub>rs11574851T</sub> allele had a significantly increased risk of developing RA whereas a non-significant effect was found in ACPA-negative patients (OR<sub>Rec-ACPA+</sub> = 1.65, 95%CI 1.04–2.63,  $P = 0.031$  vs. OR<sub>Rec-ACPA-</sub> = 0.86, 95%CI 0.39–1.90,  $P = 0.90$  and per-allele OR<sub>ACPA+</sub> = 1.39, 95%CI 1.06–1.83,  $P = 0.017$  and per-allele OR<sub>ACPA-</sub> = 1.02, 95%CI 0.68–1.52,  $P = 0.93$ ; Table 3). On the other hand, we found that seronegative subjects carrying the *KLRC*<sub>rs7301582T</sub> or *KLRK1*<sub>rs1049174C</sub> alleles showed a significantly increased risk of developing RA whereas no effect was detected in ACPA-positive individuals (OR<sub>Dom-ACPA-</sub> = 1.56, 95%CI 1.18–2.09,  $P = 0.003$  vs. OR<sub>Dom-ACPA+</sub> = 1.05, 95%CI 0.84–1.30,  $P = 0.67$  and OR<sub>Dom-ACPA-</sub> = 1.38, 95%CI 1.03–1.84,  $P = 0.031$  vs. OR<sub>Dom-ACPA+</sub> = 1.09, 95%CI 0.88–1.35,  $P = 0.42$ ).

Although none of the above-reported associations survived after correction for multiple testing, we attempted to replicate them through meta-analysis of the discovery data with those from the DANBIO registry. The meta-analysis of these two populations, which included 4194 subjects (1888 RA patients and 2306 healthy controls), confirmed that carriers of the *NFKB2*<sub>rs12769316T/T</sub> genotype had an increased risk of developing RA when compared with those carrying the C allele (OR<sub>Meta</sub> = 1.78, 95%CI 1.21–2.63,  $P = 0.0037$ ,  $I^2 = 0.0\%$ ,  $P_{Het} = 0.76$ ; Supplementary Table 2). In addition, although the association was only significant at nominal level ( $P < 0.05$ ), we also found that carriers of the *NFKB2*<sub>rs11574851T</sub> allele also had an increased risk of developing RA (OR<sub>Meta</sub> = 1.29, 95%CI 1.02–1.64,  $P = 0.035$ ,  $P_{Het} = 0.27$ ). Given that no population stratification was detected (Supplementary Table 3), these findings suggested that the effect attributed to the *NFKB2* locus on the risk of RA was likely true and might depend on a specific haplotype rather than single SNPs. Following this hypothesis, we performed an overall haplotype analysis that revealed that carriers of the *NFKB2*<sub>TC</sub> haplotype (including the *NFKB2*<sub>rs11574851T</sub> allele) had a significantly increased risk of developing RA (OR = 2.21, 95%CI 1.37–3.56,  $P = 0.0011$ ). Although


Gene	SNP ID	Chr.	Effect allele	Discovery population ACPA <sup>+</sup> RA vs. controls (n = 1971)		Replication DANBIO Registry ACPA <sup>+</sup> RA vs. controls (n = 1741)		Meta-analysis ACPA <sup>+</sup> RA vs. controls (n = 3712)		
				OR (95% CI) <sup>θ</sup>	P	OR (95% CI) <sup>θ</sup>	P	OR (95% CI) <sup>θ</sup>	P	I <sup>2</sup>
GBP6	rs928655	1	A	0.88 (0.74–1.04)	0.14	1.24 (0.97–1.58)	0.079	1.03 (0.74–1.44)	0.85	0.024
IKBKB	rs11986055	8	A	1.15 (0.83–1.62)	0.40	—	—	—	—	—
IRF4	rs1050975	6	A	<b>1.51 (1.14–1.99)<sup>§</sup></b>	<b>0.003</b>	0.93 (0.65–1.32) <sup>§</sup>	0.68	1.12 (0.74–1.93) <sup>§</sup>	0.45	0.035
IRF4	rs12203592	6	T	0.99 (0.78–1.24)	0.92	—	—	—	—	—
IRF4	rs1877175	6	T	0.86 (0.75–1.01)	0.065	1.06 (0.84–1.33)	0.61	0.93 (0.77–1.15)	0.52	0.13
IRF4	rs7768807	6	T	0.93 (0.78–1.09)	0.36	—	—	—	—	—
KLRC1	rs7301582	12	T	1.15 (0.97–1.37)	0.096	0.85 (0.67–1.08)	0.19	1.00 (0.74–1.34)	1.00	0.044
KLRK1   KLRC4	rs1049174	12	C	1.06 (0.90–1.25)	0.45	0.95 (0.76–1.19)	0.66	—	—	—
KLRK1   KLRC4	rs1154831	12	A	1.05 (0.88–1.26)	0.59	—	—	—	—	—
KLRK1   KLRC4	rs2255336	12	A	1.04 (0.87–1.25)	0.68	—	—	—	—	—
LOC105376246	rs2722824	9	A	0.93 (0.79–1.10)	0.41	—	—	—	—	—
NFKB1	rs4648110	4	A	1.16 (0.97–1.39)	0.11	—	—	—	—	—
NFKB2	rs11574851	10	T	<b>1.39 (1.06–1.83)</b>	<b>0.017</b>	<b>1.72 (1.14–2.59)</b>	<b>0.009</b>	<b>1.48 (1.18–1.86)</b>	<b>0.0006</b>	0.40
NFKB2	rs12769316	10	T	1.70 (0.95–3.06) <sup>§</sup>	0.077	1.91 (0.93–3.92) <sup>§</sup>	0.080	<b>1.78 (1.13–2.80)<sup>§</sup></b>	<b>0.013</b>	0.81
NFKB2   PSD	rs1056890	10	T	0.95 (0.81–1.12)	0.56	—	—	—	—	—
NFKBIB	rs3136645	19	C	1.15 (0.95–1.38)	0.14	—	—	—	—	—
NLRP3	rs4612666	1	T	<b>1.29 (1.04–1.60)<sup>†</sup></b>	<b>0.020</b>	1.06 (0.81–1.39) <sup>†</sup>	0.68	1.19 (0.99–1.44) <sup>†</sup>	0.072	0.27
REL	rs13031237	2	T	1.15 (0.85–1.53) <sup>§</sup>	0.36	1.15 (0.78–1.70) <sup>§</sup>	0.47	1.15 (0.91–1.45) <sup>§</sup>	0.24	1.00
REL	rs842647	2	A	1.10 (0.93–1.31)	0.27	—	—	—	—	—
REL	rs13017599	2	A	1.04 (0.89–1.21)	0.64	1.02 (0.83–1.25)	0.86	1.03 (0.91–1.17)	0.61	0.88
RELA	rs11820062	11	T	0.91 (0.78–1.05)	0.20	—	—	—	—	—
RELA	rs2306365	11	A	1.02 (0.81–1.28)	0.86	—	—	—	—	—
RELA	rs7119750	11	T	1.04 (0.82–1.30)	0.76	—	—	—	—	—
TLR10	rs11096957	4	A	1.13 (0.98–1.32)	0.10	<b>0.75 (0.60–0.93)</b>	<b>0.010</b>	0.93 (0.62–1.39)	0.72	<b>0.002</b>
TLR4	rs4986791	9	T	1.15 (0.83–1.60)	0.40	—	—	—	—	—
TLR5	rs5744174	1	C	1.03 (0.88–1.20)	0.75	—	—	—	—	—
TLR9     TWF2	rs187084	3	T	0.93 (0.80–1.09)	0.39	—	—	—	—	—
TRAF1     C5	rs3761847	9	A	1.00 (0.86–1.17)	0.99	—	—	—	—	—

**Table 4.** Meta-analysis for the association of NFKB- and inflammasome-related polymorphisms and RA risk in ACPA<sup>+</sup> patients. Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. A random effect model was assumed for the meta-analysis of both cohorts. <sup>θ</sup>Estimates calculated according to an additive model of inheritance and adjusted for age and sex. <sup>†</sup>Estimates calculated according to a dominant model of inheritance and adjusted for age and sex. <sup>§</sup>Estimates calculated according to a recessive model of inheritance and adjusted for age and sex. P < 0.05 in boldface.

this association did not survive multiple testing correction, it pointed to a role of the *NFKB2*<sub>rs11574851</sub> SNP to confer risk to RA development.

Most importantly, an ACPA-stratified meta-analysis of our data with those from the DANBIO registry also revealed that each copy of the *NFKB2*<sub>rs11574851T</sub> allele conferred an additive risk of developing RA in ACPA-positive subjects (OR<sub>Meta</sub> = 1.48, 95%CI 1.18–1.86, P = 0.0006) that was not detected in ACPA-negative individuals (Table 4 and Fig. 1). Of note, the association of the *NFKB2*<sub>rs11574851</sub> SNP with an increased risk of RA remained significant after correction for multiple testing and the direction of the effect was consistent with no significant heterogeneity between cohorts (P<sub>Het</sub> = 0.40; Fig. 1). The ACPA-stratified meta-analysis of both populations also showed an increased risk of RA in ACPA-positive and ACPA-negative subjects carrying the *NFKB2*<sub>rs12769316T/T</sub> genotype (P = 0.013 and P = 0.004; Table 4 and Supplementary Table 4). Even though none of the associations of the *NFKB2*<sub>rs12769316T/T</sub> genotype with RA remained significant after correction for multiple testing, these findings supported the notion of a relevant role of the *NFKB2* locus in modulating the RA risk. In order to further confirm this hypothesis, we decided to evaluate whether there was an ACPA-specific haplotype that could influence the risk of developing RA. Interestingly, the ACPA-stratified haplotype analysis including both the discovery and DANBIO cohorts also confirmed that ACPA-positive subjects carrying the *NFKB2*<sub>T</sub> haplotype (including the *NFKB2*<sub>rs11574851T</sub> risk allele) had a significantly increased risk of RA (OR<sub>Haplotype-ACPA+</sub> = 1.39, 95%CI 1.11–1.74, P = 0.0042) whereas no effect was detected in ACPA-negative individuals (OR<sub>Haplotype-ACPA-</sub> = 1.04, 95%CI 0.75–1.44, P = 0.82; Table 5). These results again pointed to an ACPA-specific effect of the *NFKB2* locus to modulate the risk of RA. No additional overall or ACPA-specific associations were confirmed in the meta-analysis of both cohorts.

On the basis of the effect found for the *NFKB2*<sub>rs11574851</sub> or *NFKB2*<sub>rs12769316</sub> SNPs on the risk of developing RA, we decided to analyse whether these SNPs might exert their biological function directly through the modulation of *NFKB2*-mediated immune responses or indirectly through the regulation of steroid hormone levels. To do



**Figure 1.** Association of the *NFKB2*<sub>rs11574851</sub> SNP with the risk of RA in ACPA-positive patients. Association estimates according a random effect model. **P = 0.0006.**

that we evaluated if there were any correlation between the *NFKB2*<sub>rs11574851</sub> and *NFKB2*<sub>rs12769316</sub> SNPs and levels of 9 cytokines (TNF $\alpha$ , IFN $\gamma$ , IL1 $\beta$ , IL1RA, IL6, IL8, IL10, IL17, and IL22) after stimulation of whole blood, PBMCs or macrophages with LPS, PHA or Pam3Cys in a cohort of 408 healthy subjects. Although our functional experiments were well powered, we did not find any significant correlation between the *NFKB2*<sub>rs11574851</sub> and *NFKB2*<sub>rs12769316</sub> SNPs and cytokine or steroid hormone levels (data not shown). Although these results might suggest no impact of the *NFKB2* variants in modulating immune responses, it is important to mention that we could not evaluate whether the effect of the *NFKB2*<sub>rs11574851</sub> and *NFKB2*<sub>rs12769316</sub> SNPs on the modulation of immune responses could be dependent on ACPA status as the genetic analyses indicate.

**Association of selected SNPs with the response to anti-TNF drugs.** When we evaluated the effect of any of the selected SNPs on the response to TNFi (defined as a change in DAS28 after 6 months of treatment), we found a significant effect of the *NFKB2*<sub>rs1056890</sub> SNP to modulate the response to TNFi at nominal level ( $P < 0.05$ ). Thus, each copy of the *NFKB2*<sub>rs1056890T</sub> allele additively increased the drop in DAS28 by 22% after the treatment with TNFi (per-allele OR = 1.22, 95%CI 1.03–1.44,  $P = 0.025$ ; Table 6). Importantly, when we attempted to replicate this association through a well-powered meta-analysis of our data from the discovery population with those from the DREAM and DANBIO registries ( $n = 2107$ ), we could confirm that carriers of the *NFKB2*<sub>rs1056890T</sub> allele showed a significantly higher improvement in DAS28 after treatment with TNFi (OR<sub>Meta</sub> = 1.18, 95%CI 1.05–1.33,  $P = 0.0077$ ,  $I^2 = 51.7\%$ ,  $P_{Het} = 0.13$ ; Fig. 2A). Although this association did not remain significant after correction for multiple testing and therefore need to be further validated, this finding suggested that the *NFKB2*<sub>rs1056890</sub> SNP might modulate the response to anti-TNF drugs through the regulation of the *NFKB2*-related immune responses.

In order to test this hypothesis, we assessed whether the *NFKB2*<sub>rs1056890</sub> SNP was associated with cytokine and steroid hormone levels in the HFGP cohort. Although this SNP was not included in the genome-wide association data available from the HFGP cohort, we could evaluate the association of this marker with cytokine and steroid hormone levels through the analysis of neighbouring SNPs in strong LD with it. Our stimulation experiments showed that PBMCs from carriers of the *NFKB2*<sub>rs1005044C</sub> allele (in complete LD with the rs1056890T allele,  $r^2 = 1.00$ ) showed an increased production of IL10 after stimulation of PBMCs with LPS for 24 h ( $P = 0.0025$ ; Fig. 2B). The analysis of additional neighbouring SNPs belonging to the same LD block allowed us to confirm the association of the rs1056890T allele with increased levels of IL10 (Supplementary Table 5). Although the association of the *NFKB2*<sub>rs1056890</sub> SNP with a better response to TNFi and its correlation with higher levels of IL10 did not remain statistically significant after correction for multiple testing, altogether these findings point to a role of this marker in determining the response to TNFi likely through the modulation of IL10-mediated immune responses. No significant association of the *NFKB2*<sub>rs1056890</sub> SNP with response to TNFi was observed when association analysis was stratified by ACPA, which dismissed the implication of ACPA in the functional effect attributed to this polymorphism. We did not find correlation of any of the *NFKB2* SNPs with steroid hormone levels (data not shown), which also ruled out the implication of steroid hormones in the modulation of the IL10-mediated immune responses.

## Discussion

Our data provided, for the first time, evidence that *NFKB2* locus might modulate the risk of RA. The meta-analysis of the data obtained in the discovery population with those from the DANBIO cohort showed a potentially interesting overall association of the *NFKB2*<sub>rs11574851</sub> SNP with the risk of RA that was further confirmed in an overall haplotype analysis. Most importantly, we found that the effect attributed to the *NFKB2* locus on RA risk depended on the ACPA status. An ACPA-stratified meta-analysis of the discovery and DANBIO populations including 3712 subjects revealed that ACPA-positive subjects carrying the *NFKB2*<sub>rs11574851T</sub> allele had a significantly increased risk of developing RA whereas no effect was detected in ACPA-negative individuals. Of note, the association of the *NFKB2*<sub>rs11574851T</sub> allele with an increased risk of RA in ACPA-positive subjects remained significant even after correction for multiple testing and was further confirmed in an ACPA-stratified haplotype analysis that showed that the presence of the *NFKB2*<sub>rs11574851T</sub> allele was driving the effect of the *NFKB2*<sub>TA</sub> haplotype on the risk of RA in ACPA positive subjects but not in ACPA-negative individuals.

The *NFKB2* gene is located on chromosome 10q24 and it encodes for a subunit of the *NFKB* complex (p100/p52) that is expressed in multiple immune cells and modulates the inflammation. Other important processes involved in the RA pathology such as Th1 immune responses, activation, abnormal apoptosis and osteoclast differentiation and proliferation<sup>10</sup> are also impacted. It is broadly known that RA arises as a consequence of

NFKB2	rs11574851	rs12769316	99999	Freq	RA patients (n = 4210) OR (95% CI)	P	Freq	ACPA-positive patients (n = 3117) OR (95% CI)	P	Freq	ACPA-negative patients (n = 2688) OR (95% CI)	P
1	C	C		0.8181	1.00	—	0.8224	1.00	—	0.8295	1.00	—
2	C	T		0.1139	1.14 (0.99–1.31)	0.066	0.1706	1.10 (0.92–1.32)	0.30	0.1088	1.02 (0.79–1.30)	0.91
3	T	T		0.0571	1.18 (0.98–1.42)	0.13	0.0530	<b>1.39 (1.11–1.74)</b>	<b>0.0042</b>	0.0538	1.04 (0.75–1.44)	0.82
4	T	C		0.0109	<b>2.21 (1.37–3.56)</b>	<b>0.0011</b>	—	—	—	—	—	—


**Table 5.** Overall and ACPA-stratified haplotype association analysis for RA. †Estimates calculated according to a dominant model. Minimum haplotype frequency was set at 0.01.  $P < 0.05$  in bold.

the interaction between genetic and environmental factors and that the *NFKB* pathway plays a central role in determining the onset of the disease and its progression. In addition, it has been reported that the genetic and environmental factors that predispose to RA development are substantially different between ACPA-positive and ACPA-negative subjects. Recent studies have demonstrated, for instance, that the effect attributed to the two major genetic risk factors for RA (shared epitope of the HLA-DRB1 and a SNP on the PTPN22 gene) is clearly dependent on the ACPA status having a more evident effect in ACPA-positive subjects than in those lacking of these antibodies<sup>38</sup>. Furthermore, recent GWAS studies have reported the existence of a completely different genetic component or even a gene-smoking interaction pattern between ACPA-positive and ACPA-negative patients, again suggesting a relevant role of ACPA in determining the onset of the disease<sup>39,40</sup>. However, up to now, little is known about the effect of ACPA on the control of the *NFKB* pathway. Interestingly, recent investigations have demonstrated that the treatment of PBMCs-derived macrophages with ACPA induced the activation of the *NFKB* pathway and subsequently the induction of the NLRP3-inflammasome and the production of pro-inflammatory cytokines<sup>41</sup>. Mechanistically, it was demonstrated that ACPA induces the activation of the *NFKB* pathway through the induction of the interaction between CD147 and integrin  $\beta$ 1 or ATGB1, which in turn activates the downstream Akt/*NFKB* signalling pathway, resulting in the upregulation of NLRP3 and pro-IL-1 $\beta$  expression and further NLRP3 inflammasome activation<sup>41</sup>. Considering these interesting findings, we decided to assess in the HFGP cohort if there was any correlation between the *NFKB2* SNPs and pro- and anti-inflammatory cytokine production after stimulation of whole blood, PBMCs or monocyte-derived macrophages with LPS, PHA or Pam3Cys. We also analysed whether *NFKB2* variants could indirectly affect immune responses through the modulation of steroid hormone levels. Despite the use of a large cohort of healthy subjects from the HFGP cohort, we could not find any significant correlation between the *NFKB2*<sub>rs11574851</sub> and *NFKB2*<sub>rs12769316</sub> SNPs and cytokine or steroid hormone levels. Although these results suggested that these variants might not exert their effect on RA risk through the modulation of *NFKB2*- or steroid hormone-mediated immune responses, we could not rule out the possibility of a true effect of these variants on the immune response as their effect might depend on the presence of ACPA (as suggested by our genetic data) or even specific haplotypes. In line with this hypothesis, *in silico* analysis using Haploreg data showed that the *NFKB2*<sub>rs11574851</sub> and *NFKB2*<sub>rs12769316</sub> SNPs mapped among histone marks in multiple primary T helper naïve and memory cells and primary B cells from peripheral blood and they were predicted to act as enhancers in T helper memory cells and to change motifs for Pö6fu1, AP-4, CEBPB, Mef2 and RP58. Even though these data supported the idea of a role of *NFKB2* variants in modulating immune responses, we think that additional experiments are still needed to determine whether ACPA or specific haplotypes are factors involved in modulating the effect of the *NFKB2* locus on the risk of RA.

Besides the role of the *NFKB2* locus in determining the risk of RA, this study also showed a noticeable impact of the *NFKB2* gene in the modulation of the response to TNFi. In particular, the meta-analysis of the discovery population with data from the DREAM and DANBIO registries, including 2107 RA patients, showed that carriers of the *NFKB2*<sub>rs1056890T</sub> allele had an improvement in DAS28 after treatment with TNFi. We found that the direction of the effect of the *NFKB2*<sub>rs1056890</sub> SNP on drug response was consistent across populations and that the effect was statistically significant in 2 of the 3 populations analysed. Although at this point it tempting to speculate that this SNP constitutes a biomarker for good response to TNFi in RA patients that might help to design more individualized treatment strategies, the association did not remain significant after correction for multiple testing and, therefore, need to be confirmed in independent populations. Mechanistically, we found that the presence of neighbouring genetic markers in strong LD with the *NFKB2*<sub>rs1056890</sub> SNP were associated with increased levels of IL10, suggesting that the *NFKB2* locus might be implicated in modulating IL10-mediated immune responses. Although the association of the *NFKB2*<sub>rs1056890</sub> SNP with IL10 levels neither survive correction for multiple testing, our results were in agreement with previous studies demonstrating that *NFKB2* unlikely *NFKB1* is implicated in the control of antigen presenting cell function and not in the activation of T and B cells. Likewise, recent studies have also identified genetic polymorphisms within the *NFKB* pathway as genetic biomarkers for response to TNFi in RA<sup>42</sup> but also other autoimmune diseases<sup>42</sup>, which further supported our hypothesis suggesting a key role of the *NFKB2* gene in modulating the response to TNFi. In addition, *in silico* tools such as Regulome showed that the rs1056890 SNP has a score of 4, which means that this polymorphism could affect transcription factor affinity and DNase peak<sup>43</sup>. Using haploreg it was also suggested that the *NFKB2*<sub>rs1056890</sub> SNP might play a role in modulating immune responses as it mapped among histone marks in primary T helper naïve and T helper memory cells, T regulatory and primary NK cells and it was predicted to alter binding motifs for NRSE, Sin3Ak-20 and PLAG1. These transcription factors have been implicated in bone-related diseases<sup>44</sup> and their activation results in up-regulation of multiple target genes including immune-related genes such as macrophage colony stimulator factor (MCSF) and insulin growth factor (IGF)-2.

Gene	SNP ID	Chr.	Effect allele	Discovery population (n = 604)		Replication DREAM registry (n = 882)		Replication DANBIO Registry (n = 621)		Meta-analysis (n = 2107)		
				OR (95% CI) <sup>θ</sup>	P	OR (95% CI) <sup>θ</sup>	P	OR (95% CI) <sup>θ</sup>	P	OR (95% CI) <sup>θ</sup>	P	I <sup>2</sup>
GBP6	rs928655	1	A	1.05 (0.87–1.27)	0.61	0.90 (0.80–1.00)	0.058	ND	ND	0.95 (0.82–1.10)	0.52	0.17
IKBKB	rs11986055	8	A	0.74 (0.48–1.11)	0.14	0.85 (0.66–1.07)	0.17	0.94 (0.64–1.39)	0.76	0.85 (0.71–1.02)	0.074	0.71
IRF4	rs1050975	6	A	0.95 (0.72–1.24)	0.69	0.99 (0.83–1.17)	0.87	1.24 (0.94–1.65)	0.13	1.03 (0.90–1.18)	0.67	0.33
IRF4	rs12203592	6	T	1.01 (0.77–1.33)	0.93	ND	ND	ND	ND	ND	ND	ND
IRF4	rs1877175	6	T	1.09 (0.90–1.33)	0.37	0.92 (0.82–1.13)*	0.15	0.90 (0.75–1.09)	0.30	0.96 (0.86–1.07)	0.47	0.31
IRF4	rs7768807	6	T	0.86 (0.72–1.03)	0.10	1.04 (0.93–1.16)*	0.52	ND	ND	0.96 (0.80–1.15)	0.65	0.08
KLRC1	rs7301582	12	T	1.05 (0.86–1.27)	0.62	1.00 (0.88–1.12)	0.94	0.99 (0.80–1.22)	0.92	1.00 (0.92–1.11)	0.85	0.90
KLRC1 KLRC4	rs1049174	12	C	1.08 (0.91–1.29)	0.37	0.96 (0.86–1.08)	0.53	1.07 (0.90–1.27)	0.47	1.01 (0.93–1.10)	0.79	0.42
KLRC1 KLRC4	rs1154831	12	A	0.89 (0.73–1.10)	0.28	1.05 (0.93–1.19)*	0.40	ND	ND	0.99 (0.84–1.16)	0.88	0.18
KLRC1 KLRC4	rs2255336	12	A	1.09 (0.90–1.33)	0.38	1.01 (0.89–1.16)	0.81	ND	ND	1.04 (0.93–1.15)	0.54	0.53
LOC105376246	rs2722824	9	A	1.03 (0.86–1.23)	0.77	0.94 (0.85–1.05)	0.32	ND	ND	0.96 (0.88–1.05)	0.41	0.39
NFKB1	rs4648110	4	A	1.07 (0.88–1.29)	0.51	1.00 (0.89–1.13)*	0.95	ND	ND	1.02 (0.92–1.13)	0.71	0.56
NFKB2	rs11574851	10	T	0.97 (0.73–1.29)	0.83	0.92 (0.72–1.18)*	0.53	0.78 (0.57–1.06)	0.11	0.90 (0.76–1.05)	0.18	0.57
NFKB2	rs12769316	10	T	0.92 (0.75–1.13)	0.43	ND	ND	0.86 (0.70–1.06)	0.16	0.89 (0.77–1.03)	0.12	0.65
NFKB2 PSD	rs1056890	10	T	<b>1.22 (1.03–1.44)</b>	<b>0.025</b>	1.08 (0.98–1.19)	0.11	<b>1.31 (1.10–1.57)</b>	<b>0.0030</b>	<b>1.18 (1.05–1.33)</b>	<b>0.0077</b>	0.12
NFKBIB	rs3136645	19	C	0.90 (0.73–1.11)	0.34	ND	ND	ND	ND	ND	ND	ND
NLRP3	rs4612666	1	T	1.05 (0.87–1.25)	0.62	<b>1.20 (1.05–1.37)*</b>	<b>0.006</b>	0.96 (0.80–1.14)	0.62	1.08 (0.94–1.23)	0.28	0.13
REL	rs13031237	2	T	1.07 (0.91–1.26)	0.40	1.03 (0.94–1.14)	0.49	1.08 (0.92–1.28)	0.36	1.05 (0.97–1.13)	0.21	0.86
REL	rs842647	2	A	1.03 (0.86–1.24)	0.72	0.96 (0.87–1.06)	0.45	ND	ND	0.98 (0.89–1.06)	0.57	0.51
REL	rs13017599	2	A	1.07 (0.91–1.27)	0.41	1.03 (0.94–1.14)	0.50	1.03 (0.86–1.21)	0.78	1.04 (0.96–1.12)	0.33	0.92
RELA	rs11820062	11	T	1.07 (0.90–1.26)	0.45	0.92 (0.84–1.01)*	0.081	ND	ND	0.98 (0.84–1.13)	0.74	0.12
RELA	rs2306365	11	A	0.91 (0.71–1.16)	0.45	<b>1.19 (1.03–1.37)</b>	<b>0.021</b>	ND	ND	1.06 (0.82–1.38)	0.66	0.064
RELA	rs7119750	11	T	0.93 (0.73–1.18)	0.54	ND	ND	ND	ND	ND	ND	ND
TLR10	rs11096957	4	A	1.00 (0.85–1.19)	0.98	0.99 (0.89–1.09)	0.80	ND	ND	0.99 (0.91–1.08)	0.87	0.92
TLR4	rs4986791	9	T	1.15 (0.78–1.70)	0.47	1.18 (0.98–1.41)*	0.077	ND	ND	1.18 (1.00–1.39)	0.056	0.91
TLR5	rs5744174	1	C	0.99 (0.83–1.17)	0.89	ND	ND	ND	ND	ND	ND	ND
TLR9  TWF2	rs187084	3	T	1.02 (0.86–1.21)	0.81	0.98 (0.88–1.08)*	0.67	ND	ND	0.99 (0.91–1.08)	0.83	0.69
TRAF1  C5	rs3761847	9	A	1.08 (0.91–1.29)	0.37	1.05 (0.95–1.16)	0.33	ND	ND	1.04 (0.96–1.14)	0.35	0.77

**Table 6.** Meta-analysis for the association of *NFKB*-related polymorphisms and relative change of DAS28 score ( $\Delta$ DAS28). Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. A random effect model was assumed for the meta-analysis of both cohorts. <sup>θ</sup>Estimates calculated according to an additive model of inheritance and adjusted for age, sex and country of origin (or age and sex in the replication stages). \*Estimates based on imputed genotypes. P < 0.05 in boldface. No significant heterogeneity (heterogeneity chi-squared) was observed in any meta-analysis reported above.



**Figure 2.** Meta-analysis of the association of the *NFKB2*<sub>rs1056890</sub> SNP with response to TNFi [A] and correlation with higher levels of IL10 after stimulation of PBMCs (n = 377) with LPS [B]. [A] Association estimates according to a random effect model. P<sub>Meta</sub> = 0.0077. [B] Correlation with IL10 was analysed using genotype data of the *NFKB2*<sub>rs1005044</sub> SNP, a marker in strong LD with the rs1056890 (r<sup>2</sup> = 1.00).

## Conclusions

In conclusion, this study reports, for the first time, a consistent association of the *NFKB2*<sub>rs11574851</sub> polymorphism and *NFKB2*<sub>TT</sub> haplotype with an increased risk of developing RA in ACPA-positive subjects. In addition, this study suggests a possible role of the *NFKB2* locus in the modulation of the response to TNFi. Mechanistically, the functional experiments in the 500FG cohort suggested that the effect attributed to the *NFKB2* gene in the modulation of the response to TNFi might be mediated by IL10-mediated immune responses. However, additional studies are still warranted to shed light into the biological processes that link *NFKB2* SNPs and RA risk and drug response.

## Data availability

All data used in this project have been meticulously cataloged and archived in the BBMRI-NL data infrastructure (<https://hfgp.bbMRI.nl/>) using the MOLGENIS open source platform for scientific data<sup>45</sup>. This allows flexible data querying and download, including sufficiently rich metadata and interfaces for machine processing (R statistics, REST API) and using FAIR principles to optimize Findability, Accessibility, Interoperability and Reusability<sup>46</sup>. Genetic data from the discovery and DANBIO populations can be accessed at [ftp.genyo.es](http://ftp.genyo.es) and data from the DREAM registry are available at <https://www.synapse.org/#!Synapse:syn3280809/wiki/194735> and <https://www.synapse.org/#!Synapse:syn3280809/wiki/194736>.

Received: 13 May 2019; Accepted: 7 February 2020;

Published online: 09 March 2020

## References

- Silman, A. J. & Pearson, J. E. Epidemiology and genetics of rheumatoid arthritis. *Arthritis Res.* **4**(Suppl 3), S265–272 (2002).
- McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. *N. Engl. J. Med.* **365**, 2205–2219 (2011).
- Barnes, P. J. & Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N. Engl. J. Med.* **336**, 1066–1071 (1997).
- Han, Z., Boyle, D. L., Manning, A. M. & Firestein, G. S. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. *Autoimmunity* **28**, 197–208 (1998).
- Asahara, H., Asanuma, M., Ogawa, N., Nishibayashi, S. & Inoue, H. High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis. *Biochem. Mol. Biol. Int.* **37**, 827–832 (1995).
- Marok, R. *et al.* Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. *Arthritis rheumatism* **39**, 583–591 (1996).
- Gilston, V. *et al.* NF-kappa B activation in human knee-joint synovial tissue during the early stage of joint inflammation. *Biochemical Soc. Trans.* **25**, 518S (1997).
- Miyazawa, K., Mori, A., Yamamoto, K. & Okudaira, H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. *Am. J. Pathol.* **152**, 793–803 (1998).
- Pomerantz, J. L. & Baltimore, D. Two pathways to NF-kappaB. *Mol. Cell* **10**, 693–695 (2002).
- Makarov, S. S. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. *Arthritis Res.* **3**, 200–206 (2001).
- Weih, D. S., Yilmaz, Z. B. & Weih, F. Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. *J. Immunology* **167**, 1909–1919 (2001).
- Dejardin, E. *et al.* The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. *Immun.* **17**, 525–535 (2002).
- Basak, S., Shih, V. F. & Hoffmann, A. Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system. *Mol. Cell. Biol.* **28**, 3139–3150 (2008).
- Vaira, S. *et al.* RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. *Proc. Natl Acad. Sci. U S A.* **105**, 3897–3902 (2008).
- Wu, L. *et al.* RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. *Immun.* **9**, 839–847 (1998).
- Guo, C. *et al.* NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. *Clin. Exp. Immunology* **194**, 231–243 (2018).
- Kastbom, A., Johansson, M., Verma, D., Soderkvist, P. & Rantapaa-Dahlqvist, S. CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. *Ann. Rheumatic Dis.* **69**, 723–726 (2010).
- Kastbom, A. *et al.* Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). *Rheumatol.* **47**, 415–417 (2008).
- Verma, D. *et al.* The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production. *PLoS one* **7**, e34977 (2012).
- Arnett, F. C. *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* **31**, 315–324 (1988).
- van Gestel, A. M. *et al.* Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum.* **39**, 34–40 (1996).
- Canet, L. M. *et al.* Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. *Pharmacogenet Genomics* **25**, 432–443 (2015).
- Canet, L. M. *et al.* Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: a two-stage case-control study. *Pharmacogenet Genomics* **25**, 432–443 (2015).
- Canet, L. M. *et al.* Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. *Pharmacogenet Genomics* **25**, 323–333 (2015).
- Sode, J. *et al.* Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. *Pharmacogenomics J.* **18**, 81–86 (2018).
- Liu, C. *et al.* Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. *Mol. Med.* **14**, 575–581 (2008).
- Sode, J. *et al.* Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis. *PLoS one* **10**, e0139781 (2015).
- Bek, S. *et al.* Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. *Pharmacogenomics J.* **17**, 403–411 (2017).

29. Gregersen, P. K. *et al.* REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat. Genet.* **41**, 820–823 (2009).
30. Nyholt, D. R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am. J. Hum. Genet.* **74**, 765–769 (2004).
31. Sole, X., Guino, E., Valls, J., Iniesta, R. & Moreno, V. SNPStats: a web tool for the analysis of association studies. *Bioinforma.* **22**, 1928–1929 (2006).
32. Gabriel, S. B. *et al.* The structure of haplotype blocks in the human genome. *Sci.* **296**, 2225–2229 (2002).
33. Canet, L. M. *et al.* Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. *Pharmacogenomics J.* (2018).
34. Ibfelt, E. H., Jensen, D. V. & Hetland, M. L. The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. *Clin. Epidemiol.* **8**, 737–742 (2016).
35. Li, Y. *et al.* A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans. *Cell* **167**, 1099–1110 e1014 (2016).
36. Schirmer, M. *et al.* Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. *Cell* **167**, 1897 (2016).
37. Ter Horst, R. *et al.* Host and Environmental Factors Influencing Individual Human Cytokine Responses. *Cell* **167**, 1111–1124 e1113 (2016).
38. Viatte, S. *et al.* Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. *Ann. Rheumatic Dis.* **71**, 1984–1990 (2012).
39. Padyukov, L. *et al.* A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. *Ann. Rheumatic Dis.* **70**, 259–265 (2011).
40. Jiang, X. *et al.* An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. *Rheumatol.* **55**, 149–155 (2016).
41. Dong, X. *et al.* ACPAs promote IL-1beta production in rheumatoid arthritis by activating the NLRP3 inflammasome. *Cellular & molecular immunology*, (2019).
42. Bank, S. *et al.* Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. *Alimentary pharmacology therapeutics* **49**, 890–903 (2019).
43. Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797 (2012).
44. Zhang, Y. *et al.* Endochondral ossification pathway genes and postmenopausal osteoporosis: Association and specific allele related serum bone sialoprotein levels in Han Chinese. *Sci. Rep.* **5**, 16783 (2015).
45. Swertz, M. A. *et al.* The MOLGENIS toolkit: rapid prototyping of biosoftware at the push of a button. *BMC Bioinforma.* **11**(Suppl 12), S12 (2010).
46. Wilkinson, M. D. *et al.* The FAIR Guiding Principles for scientific data management and stewardship. *Sci. Data* **3**, 160018 (2016).
47. Ovejero-Benito, M. C. *et al.* Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. *Pharmacogenomics* **18**, 631–638 (2017).
48. Kichaev, G. *et al.* Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am. J. Hum. Genet.* **104**, 65–75 (2019).
49. Iwaszko, M. *et al.* Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. *Jt. Bone Spine* **83**, 75–79 (2016).
50. Iwaszko, M. *et al.* Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. *Genes (Basel)* **9** (2018).
51. Suhre, K. *et al.* Connecting genetic risk to disease end points through the human blood plasma proteome. *Nat. Commun.* **8**, 14357 (2017).
52. Piotrowski, P., Lianeri, M., Olesinska, M. & Jagodzinski, P. P. Prevalence of the NKG2D Thr72Ala polymorphism in patients with systemic lupus erythematosus. *Mol. Biol. Rep.* **39**, 1343–1347 (2012).
53. Kabalak, G. *et al.* Association of an NKG2D gene variant with systemic lupus erythematosus in two populations. *Hum. Immunol.* **71**, 74–78 (2010).
54. Stahl, E. A. *et al.* Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat. Genet.* **42**, 508–514 (2010).
55. Eyre, S. *et al.* High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. *Nat. Genet.* **44**, 1336–1340 (2012).
56. Ali, F. R. *et al.* An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. *Br. J. Dermatol.* **168**, 864–866 (2013).
57. Varade, J. *et al.* Analysis of the REL polymorphism rs13031237 in autoimmune diseases. *Ann. Rheumatic Dis.* **70**, 711–712 (2011).
58. Chen, F. *et al.* Genetic Variation in the REL Gene Increases Risk of Behcet's Disease in a Chinese Han Population but That of PRKCQ Does Not. *PLoS one* **11**, e0147350 (2016).
59. Ellinghaus, E. *et al.* Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. *J. Invest. Dermatol.* **132**, 1133–1140 (2012).
60. Bowes, J. *et al.* Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. *Ann. Rheumatic Dis.* **71**, 1350–1354 (2012).
61. Tang, H. *et al.* TLR10 and NFKBIA contributed to the risk of hip osteoarthritis: systematic evaluation based on Han Chinese population. *Sci. Rep.* **8**, 10243 (2018).
62. Vrgoc, G. *et al.* Interleukin-17 and Toll-like Receptor 10 genetic polymorphisms and susceptibility to large joint osteoarthritis. *J. Orthop. Res.* **36**, 1684–1693 (2018).
63. Nishikawa, R. *et al.* Genetic prediction of the effectiveness of biologics for psoriasis treatment. *J. Dermatol.* **43**, 1273–1277 (2016).
64. Gebura, K. *et al.* Polymorphisms within Genes Involved in Regulation of the NF-kappaB Pathway in Patients with Rheumatoid Arthritis. *Int. J. Mol. Sci.* **18** (2017).
65. Wang, H., Zhou, S., Zhang, J., Lei, S. & Zhou, J. Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies. *Immunol. Res.* **67**, 142–150 (2019).
66. Bank, S. *et al.* Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort. *PLoS one* **10**, e0145302 (2015).
67. Bank, S. *et al.* Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. *Pharmacogenomics J.* **18**, 87–97 (2018).
68. Loft, N. D. *et al.* Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. *Pharmacogenomics J.* **18**, 494–500 (2018).
69. Oliveira-Tore, C. F. *et al.* Genetic Polymorphisms of Toll-like receptors 2 and 9 as Susceptibility Factors for the Development of Ankylosing Spondylitis and Psoriatic Arthritis. *J. Immunol. Res.* **2019**, 1492092 (2019).
70. Yi, X., Xu, E., Xiao, Y. & Cai, X. Evaluation of the Relationship Between Common Variants in the TLR-9 Gene and Hip Osteoarthritis Susceptibility. *Genet. Test. Mol. Biomarkers* **23**, 373–379 (2019).
71. Zheng, M. *et al.* Association between TLR-9 gene rs187084 polymorphism and knee osteoarthritis in a Chinese population. *Bioscience reports* **37** (2017).
72. Huang, C. M. *et al.* Association of toll-like receptor 9 gene polymorphism in Chinese patients with systemic lupus erythematosus in Taiwan. *Rheumatol. Int.* **32**, 2105–2109 (2012).

73. Bank, S. *et al.* Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. *PLoS one* **9**, e98815 (2014).
74. Cho, W. K. *et al.* Association of Polymorphisms in Toll-Like Receptors 4 and 9 with Autoimmune Thyroid Disease in Korean Pediatric Patients. *Int. J. Endocrinol.* **2017**, 2304218 (2017).
75. Bank, S. *et al.* Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. *Pharmacogenomics J.* **14**, 526–534 (2014).
76. Plenge, R. M. *et al.* TRAF1-C5 as a risk locus for rheumatoid arthritis—a genome-wide study. *N. Engl. J. Med.* **357**, 1199–1209 (2007).

## Acknowledgements

We thank all participants who have agreed to participate in this study. Authors also thank María Dolores Casares, Ángeles Molina, Carmen Oloriz for the collection of Spanish samples and Hans Jurgen Hoffmann, Marianne Thomsen, Vibeke Østergaard Thomsen, Malene Rohr Andersen, Lise Lotte B. Laursen, Helle Jørgensen, Ram Benny Christian Dessau, Niels Steen Krogh, Ulla Vogel, Paal Skytt Andersen, Ivan Brandslund, Steffen Bank, Frederik Trier Møller, Nikolai Toft and Niels Møller Andersen for the participation in collection and purification of Danish samples. We also thank the Danish Departments of Rheumatology for their implication in the collection of clinical data from RA patients included in the DANBIO cohort and the Danish Rheumatologic Biobank. Likewise, we would like to thank Teun van Herwaarden for steroid hormone measurements in serum samples from subjects ascertained through the HFGP initiative. This work was partially supported by intramural funds of GENYO and FIBAO foundation (Granada, Spain); Novo Nordisk Fonden (NNF15OC0016932, VA); and Knud og Edith Eriksens Mindefond (VA) and Gigtföreningen (A2037, A3570, VA). MGN was supported by a Spinoza grant from the Netherlands Organization for Scientific Research.

## Author contributions

R. Caliz and J. Sainz designed the study and drafted the manuscript. J. Sanchez-Maldonado, A. Moñiz-Díez, S. Muñoz-Peña, and A. Rodríguez-Ramos were responsible for genotyping. H. Canhão, A. Escudero, S.B. Sorensen, M.L. Hetland, M.A. Ferrer, B. Glintborg, I. Filipescu, E. Pérez-Pampin, P. Conesa-Zamora, A. García, A. den Broeder, S. de Vita, S.E.H. Jacobsen, E. Collantes, L. Quartuccio, J.E. Fonseca, M. Jurado, M.A. López-Nevot, M.J.H. Coenen, V. Andersen, R. Cáliz and J. Sainz coordinated the sample collection and H. Canhão, I. Filipescu, A. García, and M.A Ferrer were involved in the records review and data acquisition. M. Martínez-Bueno and J. Sainz performed data quality control and statistical analysis. M. Netea, R. Ter Horst, Y. Li provided the functional raw data and J. Sainz performed the analysis of functional data. All authors contributed to and approved the final version of the manuscript.

## Competing interests

V.A. has received compensation for consultancy and for being a member of an advisory board from MSD (Merck) and Janssen. B.G. received funding for research from AbbVie, Biogen, and Pfizer. M.L.H. received funding for research from Abbvie, Biogen, BMS, CellTrion, MSD, Novartis, Orion, Pfizer, Samsung and UCB. The rest of authors declare that they have no competing interests.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41598-020-61331-5>.

**Correspondence** and requests for materials should be addressed to J.S.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020